Physician profile
Diego C Saavedra
NPI 1689643850
$6,099.70
in general payments reported to CMS, 2019-2025
41 companies · $69.77 in 2025
The $69.77 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,791 · 2020: $411 · 2021: $1,006 · 2022: $1,501 · 2023: $1,122 · 2024: $199 · 2025: $69.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,390.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $799.95 | 2019-2023 | Repatha, Otezla |
| Novo Nordisk INC | $572.02 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $552.84 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $447.38 | 2019-2023 | Farxiga, Breztri |
| Pfizer INC. | $436.93 | 2019-2024 | |
| Abbott Laboratories | $431.77 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $406.83 | 2019-2023 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $361.57 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $212.11 | 2020-2022 | |
| Abbvie INC. | $200.30 | 2021-2023 | Ubrelvy, Synthroid, Qulipta |
| Biohaven Pharmaceutical Holding Company LTD. | $168.76 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.70 | 2019-2023 | Synjardy |
| Novartis Pharmaceuticals Corporation | $148.23 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $120.46 | 2019-2022 | |
| Exact Sciences Corporation | $84.80 | 2023 | Cologuard Collection Kit |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Saavedra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.